Welcome: Guest | Site Use Options | Register | Login |

Sarepta Therapeutics

215 First Street Suite 7
Cambridge, MA 02142
 Synopsis: Business Condition
Year Founded 1980
Employment 103
Sector Healthcare
Industry Biotechnology
Sarepta Therapeutics
     Last modified on: 8/26/2013

Sarepta Therapeutics – formerly AVI BioPharma – remains focused on developing first-in-class, RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. The company's developmental stage program includes AVI-4658, which is in phase Ib stage of clinical trial for the treatment of duchenne muscular dystrophy. Its preclinical stage programs consist of AVI-6006 for the treatment of Dengue virus; and AVI- 7100 for the treatment of H1N1 influenza virus. AVI BioPharma's programs that are authorized to enter phase I studies include AVI-6002 for the treatment of Ebola virus; and AVI-6003 for the treatment of Marburg virus. It has strategic alliance with Charley's Fund, Inc.


SBIR firms in the news

Contact information

Innovation Development Institute, LLC

   45 Beach Bluff Avenue, Suite 300
     Swampscott,  MA 01907-1542

  Tel:  (781) 595-2920